Despite the effects of dysferlin-deficiency on endothelial and vascular function, to date, atherosclerotic plaque development has not been explored in human patients or mouse models of dysferlinopathies. The gene discussed is DYSF; the disease is neuromuscular disease caused by qualitative or quantitative defects of dysferlin.